Immunovant (IMVT) Other Operating Expenses (2019 - 2023)

Immunovant (IMVT) reported Other Operating Expenses of $12.5 million for Q2 2023, up 25.0% quarter-over-quarter from $10.0 million in Q4 2022.

Immunovant (IMVT) Other Operating Expenses (2019 - 2023) Analysis & Trends

Immunovant has reported Other Operating Expenses for 3 years, with the latest figure at $12.5 million in Q2 2023.

For the quarter ending Q2 2023, Other Operating Expenses changed N/A year-over-year to $12.5 million; the trailing twelve-month figure through Mar 2024 stood at $12.5 million (up 25.0% YoY), and the FY2024 full-year result was $12.5 million, up 25.0% from the prior year.
Other Operating Expenses for Q2 2023 stood at $12.5 million, up from $10.0 million in the prior quarter.
The five-year high for Other Operating Expenses was $12.5 million in Q2 2023, with the low at -$8.9 million in Q1 2019.
Historically, Other Operating Expenses has averaged $4.5 million across 3 years, with a median of $10.0 million in 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Immunovant	5.71 Bn	5.71 Bn	-

Download Data